ACHL vs. PLUR, CRTX, INAB, BCLI, TARA, INKT, SRZN, NKGN, ZIVO, and ESLA
Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Pluri (PLUR), Cortexyme (CRTX), IN8bio (INAB), Brainstorm Cell Therapeutics (BCLI), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), Surrozen (SRZN), NKGen Biotech (NKGN), ZIVO Bioscience (ZIVO), and Estrella Immunopharma (ESLA). These companies are all part of the "medical" sector.
Pluri (NASDAQ:PLUR) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Pluri has higher revenue and earnings than Achilles Therapeutics. Pluri is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Achilles Therapeutics has a net margin of 0.00% compared to Achilles Therapeutics' net margin of -6,708.40%. Pluri's return on equity of -42.55% beat Achilles Therapeutics' return on equity.
16.6% of Pluri shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 24.3% of Pluri shares are owned by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 335.30%. Given Pluri's higher probable upside, analysts clearly believe Achilles Therapeutics is more favorable than Pluri.
In the previous week, Achilles Therapeutics had 2 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Achilles Therapeutics and 1 mentions for Pluri. Pluri's average media sentiment score of 0.00 beat Achilles Therapeutics' score of -0.41 indicating that Achilles Therapeutics is being referred to more favorably in the news media.
Pluri has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Achilles Therapeutics received 17 more outperform votes than Pluri when rated by MarketBeat users.
Summary
Achilles Therapeutics beats Pluri on 11 of the 15 factors compared between the two stocks.
Get Achilles Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achilles Therapeutics Competitors List
Related Companies and Tools
